• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?

作者信息

Zagami P, Cortés J, Carey L A, Curigliano G

机构信息

Department of Oncology and Hematology, University of Milano, Milan; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.

Oncology Department, International Breast Cancer (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas & Co, Jersey City (New Jersey, USA), Sao Paulo (Brazil); Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.

出版信息

ESMO Open. 2024 Sep;9(9):103695. doi: 10.1016/j.esmoop.2024.103695. Epub 2024 Sep 9.

DOI:10.1016/j.esmoop.2024.103695
PMID:39255535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11415669/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11415669/871241bbae62/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11415669/871241bbae62/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11415669/871241bbae62/gr1.jpg

相似文献

1
Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?激素受体阳性（HR+）早期乳腺癌治疗领域中的免疫疗法：新数据是否正在改变临床实践？
ESMO Open. 2024 Sep;9(9):103695. doi: 10.1016/j.esmoop.2024.103695. Epub 2024 Sep 9.
2
Estrogen and progesterone receptors in breast cancer.乳腺癌中的雌激素和孕激素受体
Future Oncol. 2014 Nov;10(14):2293-301. doi: 10.2217/fon.14.110.
3
Should estrogen receptor positive and progesterone receptor negative and HER-2 negative breast cancer patients be considered as a luminal B subtype?雌激素受体阳性、孕激素受体阴性且人表皮生长因子受体2阴性的乳腺癌患者应被视为腔面B亚型吗？
J BUON. 2020 Sep-Oct;25(5):2529.
4
Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.MAGE-A3/6 在原发性乳腺癌中的表达与激素受体阴性状态、高组织学分级和不良生存相关。
J Immunother. 2014 Feb-Mar;37(2):73-6. doi: 10.1097/CJI.0000000000000013.
5
Pure and mixed hormone receptor positive breast tumors: are they different from therapeutic point of view?纯激素受体阳性和混合激素受体阳性乳腺肿瘤：从治疗角度来看它们有差异吗？
Med Hypotheses. 2005;65(1):194. doi: 10.1016/j.mehy.2005.02.023.
6
The natural history of hormone receptor-positive breast cancer.激素受体阳性乳腺癌的自然病程。
Oncology (Williston Park). 2012 Aug;26(8):688-94, 696.
7
Management of hormone receptor-positive, HER2-negative early breast cancer.激素受体阳性、HER2 阴性早期乳腺癌的治疗管理。
Semin Oncol. 2020 Aug;47(4):187-200. doi: 10.1053/j.seminoncol.2020.05.010. Epub 2020 Jun 3.
8
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.原发性乳腺癌中针对 NY-ESO-1 的抗体反应可识别免疫治疗的亚组靶点。
PLoS One. 2011;6(6):e21129. doi: 10.1371/journal.pone.0021129. Epub 2011 Jun 17.
9
Hormone receptors in the management of breast cancer.
Tex Med. 1984 Nov;80(11):30-2.
10
Changing concepts of hormone receptor-positive advanced breast cancer therapy.激素受体阳性晚期乳腺癌治疗观念的转变。
Clin Breast Cancer. 2013 Jun;13(3):159-66. doi: 10.1016/j.clbc.2012.11.002. Epub 2012 Dec 8.

引用本文的文献

1
Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer.将免疫疗法纳入早期雌激素受体阳性乳腺癌的治疗中。
ESMO Open. 2024 Nov;9(11):103977. doi: 10.1016/j.esmoop.2024.103977. Epub 2024 Nov 6.